Related Experiment Video
Updated: Aug 31, 2025

Live Imaging and Quantification of Viral Infection in K18 hACE2 Transgenic Mice Using Reporter-Expressing Recombinant SARS-CoV-2
Published on: November 5, 2021
Effect on SARS-CoV-2 viral load using combination therapy with casirivimab/imdevimab and remdesivir
Vivek K Kataria1, Mezgebe Berhe2, Uriel Sandkovsky2
1Department of Pharmacy, Baylor University Medical Center, Dallas, Texas.
Abstract:
Evidence suggests that SARS-CoV-2 viral load is an independent predictor of disease severity and mortality. A 61-year-old woman presented with severe COVID-19 and was treated with casirivimab/imdevimab and remdesivir. Quantitative nasopharyngeal (NP) viral loads were trended throughout the treatment course. Baseline NP viral load was 25,860,901 copies/mL (7.4 log10). Casirivimab/imdevimab was administered, with subsequent reduction in NP viral load to 26,049 copies/mL (4.4 log10) on hospital day 4. A repeat NP viral load on day 7 was 13,113 copies/mL (4.1 log10). Despite uncertainty regarding correlation with reduction in viral load and outcomes, NP viral load may be considered when selecting treatment options and evaluating treatment response in hospitalized patients with early infection.
Related Concept Videos
Combined Effects of Drugs: Synergism
Such synergistic combinations...
Retrovirus Life Cycles
Subviral Agents
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Antimicrobial Effectiveness
Time Course of Drug Effect

